Considering high-dose EPA/DHA as a primary option for migraine prevention

Key clinical point: High-dose eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) supplementation demonstrated highest efficacy and acceptability among all studied treatments, emphasizing its potential as a first-choice treatment for migraine prophylaxis.

Major finding: Among all prophylactic treatments, high-dose EPA/DHA supplementation showed the highest decrease in migraine frequency (standardized mean difference [SMD] ─1.36; 95% CI ─2.32 to ─0.39) and severity (SMD ─2.23; 95% CI ─3.17 to ─1.30) and the most favorable acceptability rate (odds ratio 1.00; 95% CI 0.06 to 17.41) compared with placebo.

Study details: The data come from a network meta-analysis of 40 randomized controlled trials that included 6616 patients with either episodic or chronic migraine.

,

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Tseng PT et al. Efficacy of high dosage anti-inflammatory eicosapentaenoic acid/docosahexaenoic acid for migraine prophylaxis: A network meta-analysis. Adv Nutr. 2023;15(2):100163 (Dec 16). doi: 10.1016/j.advnut.2023.100163